Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1540)	2/6/2006 1:45:19 PM
From: zeta1961	Read Replies (1) \| Respond to of 3722

<ISRG>not technically biotech..they make robots for surgical suites though-g- Bernard, is this one on any of your screens?..I've been keeping a 1/2 eye since I missed the run-up..although great earnings last Friday they predicted somewhat lower '06 sales which is more about them predicting that hospitals will wait for their upgraded product roll-out later this year..this co. has done a fantastic turn around and they plan to expand beyond prostate surgery into ortho, gynecology, etc.. They're taking a huge beating since Friday.. finance.yahoo.com Thanks in advance(but no rush) Elisabeth

To: Jibacoa who wrote (1540)	10/11/2007 9:08:48 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

Expect CRGN to open on a DG today after news. bigcharts.marketwatch.com CRGN announced that its PII of velafermin for oral mucositis did not meet its primary endpoint, although it was found to be safe and well-tolerated.<g> Based on these results, CRGN is discontinuing the development of velafermin, and will continue to focus its resources on belinostat, a histone deacetylase inhibitor, which is in a PII for the treatment of solid tumors and hematologic malignancies, and CR011-vcMMAE, an antibody-drug conjugate, which is on a PI/II for the treatment of metastatic melanoma. The insiders did some buying in Aug but CRGN has a good amount of resistance at the $2 level & with today's news, it seems that it will do well if it can keep above $1 <g> The stock remains on the DT coming from its Jan H at $5 bigcharts.marketwatch.com Bernard